Recurrent aphthous stomatitis (also known as recurrent aphthous ulcers or canker sores) is the most frequently occurring ulcerative disease of the lining of the mouth. The clinical term for canker sores is Recurrent Aphthous Ulcer or RUA. As classically described, RUAs are painful shallow ulcers that are round and have a well-defined erythematous margin with yellow pseudomembranes in their center. RUAs usually occur in healthy people but also are seen with immunologic diseases. They are typically located on the cheeks, gums, and tongue. Potential causes of RAUs include vitamin deficiencies, oral flora, psychosocial stress and immune dysregulation. Although most RAUs are called minor forms and are less than 1 cm in diameter. Minor RAUs heal spontaneously within 1 week. Severe forms of RAU are larger than 1 cm in diameter, may take more than 30 days to heal, and may cause scarring of the mouth. Up to 50% of people are affected by RAUs.
A variety of medications are used to treat RAUs. Topical medications that are applied to ulcers include emollients. These medications, in the form of gels or pastes, are also known as lubricating agents. They work by forming an occlusive oily film over the oral mucosa. This in turn enhances mucosal water retention and thus decreases transmucosal water loss. Topical antiseptic agents such as chlorhexidine are also recommended for RAUs. Stronger oral treatments for RAUs include topical corticosteroids and antibiotics. Compounded medications, often containing lidocaine as a local anesthetic are commonly used to reduce pain that is associated with RAUs.
Topical oral medications are quickly eliminated from the oral cavity due to mouth movements, salivary dilution, and swallowing.
These factors may limit the efficacy of oral topical medications for RAUs.
Bocaliner has the potential to improve the effectiveness of these treatments by prolonging their retention and increasing their concentration inside of the mouth.
This in turn should amplify the effects of these topical medications. From a clinical standpoint, Bocaliner has been designed to increase the potential of topical medications to treat RAUs.
© E2Bio Life Sciences